| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 472 | 2021 |
| A phase 2 trial of the effect of antiandrogen therapy on COVID-19 outcome: no evidence of benefit, supported by epidemiology and in vitro data K Welén, E Rosendal, M Gisslén, A Lenman, E Freyhult, ... European urology 81 (3), 285-293, 2022 | 53 | 2022 |
| Rehabilitation needs following COVID-19: Five-month post-discharge clinical follow-up of individuals with concerning self-reported symptoms C Wahlgren, A Divanoglou, M Larsson, E Nilsson, ÅÖ Balkhed, K Niward, ... EClinicalMedicine 43, 2022 | 52 | 2022 |
| Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study C Wahlgren, G Forsberg, A Divanoglou, ÅÖ Balkhed, K Niward, S Berg, ... The Lancet Regional Health–Europe 28, 2023 | 37 | 2023 |
| Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma X Zheng, EM Jongedijk, Y Hu, J Kuhlin, R Zheng, K Niward, J Paues, B Xu, ... Journal of Chromatography B 1158, 122397, 2020 | 21 | 2020 |
| Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones … K Niward, K Ängeby, E Chryssanthou, J Paues, J Bruchfeld, P Jureen, ... Journal of Antimicrobial Chemotherapy 71 (2), 333-338, 2016 | 21 | 2016 |
| Individualised dosing algorithm and personalised treatment of high‐dose rifampicin for tuberculosis RJ Svensson, K Niward, L Davies Forsman, J Bruchfeld, J Paues, ... British journal of clinical pharmacology 85 (10), 2341-2350, 2019 | 20 | 2019 |
| Distribution of plasma concentrations of first-line anti-TB drugs and individual MICs: a prospective cohort study in a low endemic setting K Niward, L Davies Forsman, J Bruchfeld, E Chryssanthou, O Carlström, ... Journal of Antimicrobial Chemotherapy 73 (10), 2838-2845, 2018 | 20 | 2018 |
| Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China LD Forsman, K Niward, J Kuhlin, X Zheng, R Zheng, R Ke, C Hong, ... European Respiratory Journal 57 (3), 2021 | 16 | 2021 |
| COVIDENZA-A prospective, multicenter, randomized PHASE II clinical trial of enzalutamide treatment to decrease the morbidity in patients with Corona virus disease 2019 (COVID … K Welén, AK Överby, C Ahlm, E Freyhult, D Robinsson, AJ Henningsson, ... Trials 22, 1-3, 2021 | 11 | 2021 |
| Sedimentation rate and suPAR in relation to disease activity and mortality in patients with tuberculosis H Schulman, K Niward, E Abate, J Idh, P Axenram, A Bornefall, ... The International Journal of Tuberculosis and Lung Disease 23 (11), 1155-1161, 2019 | 11 | 2019 |
| Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study … LD Forsman, K Niward, Y Hu, R Zheng, X Zheng, R Ke, W Cai, C Hong, ... BMJ open 8 (9), e023899, 2018 | 8 | 2018 |
| Cognitive dysfunction in post‐COVID‐19 condition: Mechanisms, management, and rehabilitation M Möller, K Borg, C Janson, M Lerm, J Normark, K Niward Journal of Internal Medicine 294 (5), 563-581, 2023 | 7 | 2023 |
| Rehabilitation needs following COVID-19: Five-month post-discharge clinical follow-up of individuals with concerning self-reported symptoms. EClinicalMedicine. 2022; 43: 101219 C Wahlgren, A Divanoglou, M Larsson, E Nilsson, Å ÖstholmBalkhed, ... | 7 | 2021 |
| Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report K Nyström, M Hjorth, R Fust, Å Nilsdotter-Augustinsson, M Larsson, ... BMC Infectious Diseases 22 (1), 362, 2022 | 6 | 2022 |
| Plasma levels of rifampin correlate with the tuberculosis drug activity assay K Niward, L Ek Blom, L Davies Forsman, J Bruchfeld, E Eliasson, T Schön, ... Antimicrobial Agents and Chemotherapy 62 (5), 10.1128/aac. 00218-18, 2018 | 6 | 2018 |
| Population pharmacokinetics and dose evaluations of linezolid in the treatment of multidrug-resistant tuberculosis H Zhang, Y He, L Davies Forsman, J Paues, J Werngren, K Niward, ... Frontiers in Pharmacology 13, 1032674, 2023 | 4 | 2023 |
| Population Pharmacokinetics and Dose Evaluation of Cycloserine among Patients with Multidrug-Resistant Tuberculosis under Standardized Treatment Regimens Y Zhu, L Zhu, L Davies Forsman, J Paues, J Werngren, K Niward, T Schön, ... Antimicrobial Agents and Chemotherapy 67 (5), e01700-22, 2023 | 3 | 2023 |
| Population pharmacokinetics and model-based dosing evaluation of bedaquiline in multidrug-resistant tuberculosis patients G Shao, Z Bao, L Davies Forsman, J Paues, J Werngren, K Niward, ... Frontiers in Pharmacology 14, 1022090, 2023 | 3 | 2023 |
| Extrapulmonary Tuberculosis J Bruchfeld, LD Forsman, G Fröberg, K Niward Essential Tuberculosis, 259-266, 2021 | 3 | 2021 |
